Market Overview

UPDATE: J.P. Morgan Reiterates Neutral Rating, Raises PT on Boston Scientific Corporation

Related BSX
Benzinga's Top Initiations
Sterne Agee Initiates Boston Scientific At Neutral

In a report published Monday, J.P. Morgan reiterated its Neutral rating on Boston Scientific Corporation (NYSE: BSX), and slightly raised its price target from $6.50 to $7.00.

J.P. Morgan noted, “While we see no easy fixes to Boston's challenges, there are strategic options that we believe could be implemented to create value for shareholders. Arguably the easiest and most immediate of these would be for the Board to authorize a substantial dividend. Value could also be unlocked by separating the company's growth assets (Endoscopy, Urology, and Neuro) from its Cardiovascular franchises. With CEO Mike Mahoney now settling into his new role following a protracted leadership transition, we will be looking for signs that management is receptive to these types of measures. In the meantime, with upside from current levels limited, in our view, we rate BSX shares Neutral.”

Boston Scientific Corporation closed on Friday at $6.86.

Posted-In: J.P. MorganAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (BSX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters